keyword
MENU ▼
Read by QxMD icon Read
search

Cancer related anemia

keyword
https://www.readbyqxmd.com/read/29158367/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-of-necuparanib-combined-with-nab-paclitaxel-and-gemcitabine-in-patients-with-metastatic-pancreatic-cancer-phase-i-results
#1
Eileen M O'Reilly, James Roach, Paul Miller, Kenneth H Yu, Catherine Tjan, Molly Rosano, Silva Krause, William Avery, Julie Wolf, Keith Flaherty, Darrell Nix, David P Ryan
LESSONS LEARNED: Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.Safety was documented, although dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity (cellulitis), and low-level anticoagulant effect. Nonetheless, the hypothesis of targeting prothrombotic pathways in pancreas adenocarcinoma remains compelling...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29157782/comparative-assessment-of-the-effect-of-hyper-glycosylation-on-the-pattern-and-kinetics-of-degradation-of-darbepoetin-alfa-using-a-stability-indicating-orthogonal-testing-protocol
#2
Eman M Moenes, Medhat A Al-Ghobashy, Abeer A Mohamed, Maissa Y Salem
Darbepoetin alfa (DA); hyper-glycosylated Erythropoietin alfa (EPO) is an essential treatment of anemia in patients with chronic kidney failure and cancer. In this study, DA and EPO were subjected to physicochemical stress factors that might be encountered during production, transport and storage (pH, temperature, agitation, repeated freeze-thaw and oxidation). An orthogonal stability-indicating assay protocol comprised of SE-HPLC, RP-HPLC, ELISA and SDS-PAGE was developed and validated to investigate the effect of further glycosylation of DA on the pattern and kinetics of degradation...
November 4, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29156802/efficacy-and-safety-of-first-line-pemetrexed-plus-carboplatin-followed-by-single-agent-pemetrexed-maintenance-in-elderly-chinese-patients-with-non-squamous-non-small-cell-lung-cancer
#3
Xinmin Zhao, Hui Yu, Jing Zhao, Xianghua Wu, Si Sun, Zhiguo Luo, Huijie Wang, Jie Qiao, Jianhua Chang, Jialei Wang
Chemotherapy with pemetrexed plus carboplatin followed by pemetrexed maintenance therapy is a first-line regimen for patients with advanced non-squamous non-small-cell lung cancer. This phase II clinical study investigated the efficacy and safety of this regimen in older patients (aged ≥65 years) with advanced non-squamous non-small-cell lung cancer. All patients received 4 courses of induction therapy with pemetrexed (500 mg/m(2)) combined with carboplatin once every 3 weeks. If patients had stable disease or achieved a complete or partial tumor response after 4 courses of pemetrexed + carboplatin therapy, maintenance treatment with pemetrexed monotherapy was administered until either disease progression or intolerable toxicity occurred...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29154796/treatment-of-cancer-by-low-intensity-laser-radiation-therapy
#4
REVIEW
Sahar E Abo-Neima
Cancer treatment is one of the main challenges that face the scientific centers all over the world. The cancer incidence percentage increases year after year. The most used treatment for cancer is chemotherapy which is an application of systemic cytotoxic drug inside the patient. There are two main problems in chemotherapy that the cytotoxic drug is given systematically and cannot be localized in the tumor region in most cases that lead to killing the cancer cells as well as normal cells; and that cause the chemotherapy side effects like anemia, decrease in all blood cells count and platelets, nausea, vomiting, diarrhea, hair and nails loss and may cause a kind of blood toxicity...
November 14, 2017: Progress in Biophysics and Molecular Biology
https://www.readbyqxmd.com/read/29153775/weekly-paclitaxel-and-carboplatin-plus-bevacizumab-as-first-line-treatment-of-metastatic-triple-negative-breast-cancer-a%C3%A2-multicenter-phase-ii-trial-by-the-hellenic-oncology-research-group
#5
Emmanouil Saloustros, Michail Nikolaou, Konstantinos Kalbakis, Aris Polyzos, Charalampos Christofillakis, Nikolaos Kentepozidis, Nikolaos Pistamaltzian, Charalampos Kourousis, Lampros Vamvakas, Vasilios Georgoulias, Dimitris Mavroudis
BACKGROUND: Triple-negative breast cancer (TNBC) lacks a standard targeted therapeutic strategy and is treated with conventional cytotoxic agents. Because of the sensitivity of TNBC to platinum compounds and the synergistic effect of bevacizumab with paclitaxel we investigated the efficacy and toxicity of weekly paclitaxel and carboplatin in combination with bevacizumab as first-line treatment in metastatic TNBC. PATIENTS AND METHODS: This phase II study followed the Simon's 2-stage optimal design...
October 24, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29134668/factors-affecting-patient-reported-outcomes-after-red-blood-cell-transfusion-in-medical-patients
#6
Ka Lok Luke Chan, Wai Man Vivien Mak, Yat Hung Tam, Kwok Kuen Harold Lee
BACKGROUND: Physical variables like mortality or cardiac events were used to evaluate the requirement of red blood cell (RBC) transfusion. However, patient-reported outcomes (PROs) of blood transfusion recipients were seldom assessed. The health-related quality of life (HRQoL) of patients before and after RBC transfusion was compared in this study. STUDY DESIGN AND METHODS: The study period was February to June 2016. Standardized generic and anemia symptom-specific HRQoL instruments were administered to patients receiving RBC transfusion in the medical unit of a single center...
November 13, 2017: Transfusion
https://www.readbyqxmd.com/read/29127609/gender-based-differences-in-a-population-based-cohort-with-celiac-disease-more-alike-than-unalike
#7
Claire L Jansson-Knodell, Katherine S King, Joseph J Larson, Carol T Van Dyke, Joseph A Murray, Alberto Rubio-Tapia
BACKGROUND: There is a gap in research focused on gender-based differences in non-referral populations with celiac disease. AIMS: The aim of this study was to estimate those differences in a unique population-based cohort of patients with celiac disease with respect to (1) presenting symptoms, (2) associated autoimmune disorders, and (3) survival. METHODS: Clinical data were systematically abstracted from the electronic medical record of a population-based incident cohort of patients with celiac disease...
November 10, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29116407/fatigue-and-health-related-quality-of-life-in-anemic-patients-with-lymphoma-or-multiple-myeloma
#8
Pere Gascón, Reyes Arranz, Joan Bargay, Fernando Ramos
PURPOSE: The purpose of this study was to describe perceptions of fatigue in anemic patients with lymphoma or multiple myeloma (MM). METHODS: This is an observational multicenter study in a prospective cohort of lymphoma and MM patients with hemoglobin ≤ 11 g/dl managed under clinical practice. Fatigue was assessed at baseline and after 3 months using the PERFORM questionnaire, the Functional Assessment of Cancer Therapy-Fatigue, the linear analogue self-assessment, and visual analogue scale (VAS) scales...
November 7, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29089814/a-case-of-metastatic-prostate-cancer-and-immune-thrombocytopenia
#9
D M Betsch, S Gray, S E Zed
Prostate cancer frequently metastasizes to bone, but bone marrow involvement is relatively less common. In advanced prostate cancer, significant bone marrow infiltration can result in hematologic abnormalities such as anemia and thrombocytopenia. We report the case of a patient who presented with a new diagnosis of thrombocytopenia at the same time that he presented with prostate cancer metastatic to bone. He was found to have immune thrombocytopenia (itp) which responded to treatment with steroids. We discuss this case and review the literature on itp in the setting of advanced malignancy...
October 2017: Current Oncology
https://www.readbyqxmd.com/read/29089225/rates-and-risk-factors-of-conversion-hip-arthroplasty-after-closed-reduction-percutaneous-hip-pinning-for-femoral-neck-fractures-a-population-analysis
#10
Cynthia A Kahlenberg, Shawn S Richardson, William W Schairer, Michael B Cross
BACKGROUND: Closed reduction with percutaneous pinning (CRPP) for nondisplaced or valgus impacted femoral neck fractures is a relatively low-risk operation that can produce excellent union rates in some patients; however, failure can occur in selected patients requiring conversion to arthroplasty. The primary aim of this study was to perform a population-level analysis to determine the rate and timeframe of conversion from CRPP to total hip arthroplasty (THA) or hemiarthroplasty. METHODS: The PearlDiver database was queried from 2007-2015 for all patients who underwent CRPP for a femoral neck fracture...
October 10, 2017: Journal of Arthroplasty
https://www.readbyqxmd.com/read/29075104/risk-of-severe-hematologic-toxicities-in-cancer-patients-treated-with-parp-inhibitors-a-meta-analysis-of-randomized-controlled-trials
#11
Jian Xin Zhou, Li Jin Feng, Xi Zhang
PURPOSE: Hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied. Therefore, we conducted a meta-analysis of published clinical trials to investigate the incidence and relative risks (RRs) of severe (high-grade) hematologic events in cancer patients treated with PARPis. METHODS: PubMed, Embase, and oncology conference proceedings were searched for relevant studies...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29066689/-analysis-of-patients-who-received-enteral-nutrition-in-the-course-of-chemotherapy
#12
Junji Kawada, Masaya Nishino, Tomoki Hata, Takayuki Ogino, Hiromitsu Hoshino, Miho Okano, Kenichi Nagai, Yongkook Kim, Masaki Okuyama, Toshimasa Tsujinaka
BACKGROUND: Chemotherapy-related adverse events can deteriorate the quality of life, as well as chemotherapy tolerance, for patients with gastric cancer. Nutritional support may prevent chemotherapy-related adverse events. METHODS: Five patients who received chemotherapy for advanced gastric cancer were prescribed enteral nutrition(Elental®or ENEVO®). We retrospectively evaluated the efficacy and safety of chemotherapy while receiving enteral nutrition. RESULTS: All patients consumed more than one bottle of enteral nutrition during chemotherapy...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29056075/an-updated-review-of-the-jak1-2-inhibitor-ruxolitininb-in-the-philadelphia-negative-myeloproliferative-neoplasms
#13
Natalia Curto-Garcia, Claire N Harrison
Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide. Studies have demonstrated that Rux improves disease-related symptoms and splenomegaly. A late emerging observation from two Phase III trials was that Rux was associated with survival advantage in comparison with placebo or other available therapies in myelofibrosis. Important data suggest that for polycythemia vera Rux improved control of blood counts...
October 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/29038432/efficacy-and-safety-for-apatinib-treatment-in-advanced-gastric-cancer-a-real-world-study
#14
Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to explore factors associated with efficacy. Between January 2015 and February 2017, totally 36 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction (GEJ) were enrolled and followed up retrospectively after failing at least two lines of systemic therapy. The mPFS was 2.65 months (95%CI 1...
October 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29027591/clinical-toxicity-of-antibody-drug-conjugates-a-meta-analysis-of-payloads
#15
REVIEW
Joanna C Masters, Dana J Nickens, Dawei Xuan, Ronald L Shazer, Michael Amantea
Background Antibody drug conjugates (ADCs) utilize a monoclonal antibody to deliver a cytotoxic payload specifically to tumor cells, limiting exposure to healthy tissues. Major clinical toxicities of ADCs include hematologic, hepatic, neurologic, and ophthalmic events, which are often dose-limiting. These events may be off-target effects caused by premature release of payload in circulation. A meta-analysis was performed to summarize key clinical safety data for ADCs by payload, and data permitting, establish a dose-response model for toxicity incidence as a function of payload, dose/regimen, and cancer type...
October 13, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29019951/chemotherapy-related-toxicity-nutritional-status-and-quality-of-life-in-precachectic-oncologic-patients-with-or-without-high-protein-nutritional-support-a-prospective-randomized-study
#16
Monika Ziętarska, Joanna Krawczyk-Lipiec, Leszek Kraj, Renata Zaucha, Sylwia Małgorzewicz
BACKGROUND: Cancer disease is usually associated with impaired nutritional status, which is one of the factors contributing to deterioration of the results of surgery, chemotherapy or radiotherapy. OBJECTIVES: The aim of the study was to determine whether nutritional support with high protein (ONS) in adult oncologic patients in the first step of cancer cachexia-asymptomatic precachexia, has an influence on the toxicity of systemic therapy. However, secondary endpoints were established: to determine whether high protein ONS influences the nutritional status, the quality of life, and the performance status...
October 11, 2017: Nutrients
https://www.readbyqxmd.com/read/28960399/role-of-intracystic-cytokines-and-nitric-oxide-in-ovarian-neoplasms
#17
A Martins-Filho, M P Jammal, D C Micheli, B M Tavares-Murta, R M Etchebehere, E F C Murta, R S Nomelini
The development of new biomarkers for the diagnosis and prognosis of ovarian cancer may provide an opportunity for new therapies. In this study, we aimed to compare cytokines (interleukin [IL]-2, IL-5, IL-6, IL-8, IL-10 and tumour necrosis factor [TNF]-α) and nitric oxide (NO) metabolite levels in non-neoplastic tumours, benign primary ovarian tumours and malignant primary ovarian neoplasms. The secondary aim was to relate cytokine and intracystic NO metabolite levels to clinical, laboratory and pathologic characteristics for patients with primary ovarian malignancies...
September 28, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28946142/short-infusion-trabectedin-in-heavily-pretreated-ovarian-cancer-patients-a-single-institution-experience
#18
Claudia Marchetti, Angela Musella, Alessia Romito, Laura Vertechy, Innocenza Palaia, Violante Di Donato, Serena Boccia, Francesca De Felice, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. METHOD: Trabectedin 0.6 mg/m2 was administered as a 3-h infusion every 10 days on a 21-day cycle. The study population was compared to patients treated with weekly paclitaxel 80 mg/m2 intravenously on days 1, 8, 15, and 22 every 4 weeks. RESULTS: We identified 34 patients previously submitted to at least 3 lines of chemotherapy who received single-agent trabectedin between 2010 and 2015...
September 26, 2017: Oncology
https://www.readbyqxmd.com/read/28936560/multicenter-phase-ii-study-of-trastuzumab-plus-s-1-alone-in-elderly-patients-with-her2-positive-advanced-gastric-cancer-jaccro-gc-06
#19
Yutaka Kimura, Masashi Fujii, Toshiki Masuishi, Kazuhiro Nishikawa, Chikara Kunisaki, Satoshi Matsusaka, Yoshihiko Segawa, Masato Nakamura, Kinro Sasaki, Narutoshi Nagao, Yukimasa Hatachi, Yasuhiko Yuasa, Shinya Asami, Masahiro Takeuchi, Hiroshi Furukawa, Toshifusa Nakajima
BACKGROUND: S-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. In the HERBIS-1 trial, trastuzumab combined with S-1 plus cisplatin showed promising antitumor activity in patients with HER2-positive AGC. However, cisplatin has several important drawbacks, including vomiting and renal toxicity...
September 21, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28924235/single-nucleotide-polymorphisms-of-nucleotide-excision-repair-pathway-are-significantly-associated-with-outcomes-of-platinum-based-chemotherapy-in-lung-cancer
#20
Xiao Song, Shiming Wang, Xuan Hong, Xiaoying Li, Xueying Zhao, Cong Huai, Hongyan Chen, Zhiqiang Gao, Ji Qian, Jiucun Wang, Baohui Han, Chunxue Bai, Qiang Li, Junjie Wu, Daru Lu
Nucleotide excision repair (NER) pathway plays critical roles in repairing DNA disorders caused by platinum. To comprehensively understand the association between variants of NER and clinical outcomes of platinum-based chemotherapy, 173 SNPs in 27 genes were selected to evaluate association with toxicities and efficiency in 1004 patients with advanced non-small cell lung cancer. The results showed that consecutive significant signals were observed in XPA, RPA1, POLD1, POLD3. Further subgroup analysis showed that GTF2H4 presented consecutive significant signals in clinical benefit among adenocarcimoma...
September 18, 2017: Scientific Reports
keyword
keyword
34939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"